Cristiana Sessa

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor

Phase 1

Completed

Conditions: Breast Cancer
NSCLC
Endometrial Cancer
Ovary Cancer
Small Cell Lung Cancer (SCLC)
Head and Neck (HNSCC)

Interventions: Drug: PF-05212384
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2014-02-24

Last Posted Date: 2019-05-21

Lead Sponsor: Cristiana Sessa

Target Recruit Count: 17

Registration Number: NCT02069158

Locations: 🇨🇭
Oncology Institute of Southern Switzerland (IOSI), Bellinzona, TI, Switzerland

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

Phase 1

Completed

Conditions: B-cell Lymphoma Refractory

Interventions: Drug: Inotuzumab Ozogamicin
Drug: Temsirolimus

First Posted Date: 2012-02-20

Last Posted Date: 2016-06-07

Lead Sponsor: Cristiana Sessa

Target Recruit Count: 25

Registration Number: NCT01535989

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
🇨🇭
InselSpital, Universitätsspital Bern, Bern, Switzerland
🇨🇭
Kantonsspital St.Gallen, San Gallen, Switzerland

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy